![]() “Certain drugs will prevent disease relapses and may reduce disability progression, so this diagnostic information will help health care providers and their patients with treatment options.”ĭr. “We’ve learned that if patients are positive for MOG antibodies, and they have an attack (such as optic neuritis), and they persistently remain positive when tested six to 12 months later, they have a higher likelihood for a relapse,” says Andrew McKeon, M.B., B.Ch., M.D., a clinical biochemist and co-director of Mayo’s Neuroimmunology Laboratory. The researchers also found that persistence of the MOG antibody is associated with disease relapses, thus warranting relapse-preventing immunotherapy. “While many IDDs that mimic multiple sclerosis are rare, correct and early diagnosis allows for early immunotherapy with immunosuppressants, rather than disease-modifying agents that are commonly used in treating MS,” Dr. “And, more important, some MS treatments have been reported to worsen the disease of patients diagnosed with an IDD that is not classical MS.” “From our years of research, we have learned that if patients test positive for MOG antibodies, it generally indicates that it’s not classical MS,” says Sean Pittock, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neuroimmunology Laboratory. But why is this sticky protein so important? The test uses live cells to identify patients who are positive for an antibody to myelin oligodendrocyte glycoprotein (or “MOG,” for short). Neurologic-related diseases commonly affect the brain, optic nerves and the spinal cord, and this new test can distinguish other IDDs such as neuromyelitis optica, acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis from multiple sclerosis (MS). clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder. Mayo Clinic has launched a first-in-the-U.S. ![]() The test results can assist health care providers with treatment choices, improving patient care.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |